BCR-ABL1 compound mutations drive ponatinib resistance
- PMID: 25367954
- DOI: 10.1158/2159-8290.CD-RW2014-186
BCR-ABL1 compound mutations drive ponatinib resistance
Abstract
BCR-ABL1 compound mutations harboring T315I are resistant to multiple TKIs, including ponatinib.
©2014 American Association for Cancer Research.
Comment on
-
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14. Cancer Cell. 2014. PMID: 25132497 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
